Trial Profile
A phase IIb study investigating ischaemia-tolerant allogeneic mesenchymal bone marrow cells in patients with heart failure and reduced ejection fraction due to coronary artery disease and/or primary cardiomyopathy
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2019
Price :
$35
*
At a glance
- Drugs Ischaemia-tolerant mesenchymal stem cells (Primary)
- Indications Cardiomyopathies; Coronary artery disease; Heart failure
- Focus Therapeutic Use
- 07 Jan 2019 According to a Stemedica Cell Technologies media release, following a meeting with the FDA anticipated in the first half of 2019, Stemedica plans to initiate a Phase IIb trial.
- 18 Apr 2018 According to a CardioCell media release, the company is planning this trial at at MedStar Heart & Vascular Institute.
- 03 Dec 2015 New trial record